Navigation Links
InNexus Lead Candidate DXL625 Outperforms Rituxan in Additional Animal Studies
Date:9/16/2008

- Biotech Begins to Demonstrate Strategy to Expand NHL Marketplace with Novel Antibody and Speedy DXL Screening Preclinical Development Program -

BRITISH COLUMBIA, Canada, Sept. 16 /PRNewswire-FirstCall/ -- InNexus Biotechnology Inc. (TSX VENTURE: IXS; OTC Bulletin Board: IXSBF; http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its technology, Dynamic Cross Linking (DXL(TM)), announced today the results of an extensive mouse tumor study demonstrating superiority of InNexus' DXL625 (CD20) versus Rituxan(R) in the xenograft model.

InNexus plans to submit the data for publication along with additional data from animal studies recently completed and presented at the American Association for Cancer Research (AACR) 2008 Annual Conference. The company has also launched a large scale study of DXL625 with primates, designed to evaluate toxicity and pharmokinetics, enabling the company to move the product to the FDA toward human testing.

"A study performed by an independent group investigating the survival of mice intravenously injected with B-lymphoma cells and treated subsequently with DXL625 showed a significant improvement in outcome compared to animals treated with equivalent doses of Rituxan(R), a commercially available anti-CD20 antibody," said Dr. Thomas Kindt, InNexus' Chief Scientific Officer. "Animals treated with either drug had a superior outcome when compared to those receiving inactive control (vehicle), however DXL625 had a substantial advantage over the competing antibody. We are confident that these results will translate to therapeutic advantage when DXL625 is used in human subjects."

"The DXL(TM) technology platform builds better antibodies and soon you'll be able to see our strategy to expand the NHL marketplace. We enhance an antibody's potency in a real, measurable and predictable fashion," said Jeff Morhet, Chairman and Chief Executive Officer. "I'm pleased with our scientific progress, regulatory plans and soon we'll be well positioned to begin formal discussions with the FDA."

About DXL(TM) Technology Platform

DXL(TM) technology works by integrating self-binding peptides into monoclonal antibodies, potentiating target binding. Modified antibodies "cluster" upon engaging the target receptor site, resulting in greater "molecular mass" at the point of association. DXL(TM) antibodies have significantly extended dissociation rates, as measured by surface plasmon resonance. As a consequence, this may facilitate cancer cell destruction in a target dependent manner by increasing apoptosis, antibody dependent cell cytotoxicity and complement-dependent cytotoxicity. To learn more about InNexus' DXL(TM) technology, please visit http://www.ixsbio.com.

About InNexus

InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its DXL(TM) technology, which improves the potency of new and existing antibody products while opening new markets and disease applications. DXL(TM) antibodies utilize unique, novel and patented methods and technologies of InNexus.

InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own in- house developmental facilities. These development resources provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit http://www.ixsbio.com.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward-looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control that may cause actual results or performance to differ materially from those currently anticipated in such statements.


'/>"/>
SOURCE InNexus Biotechnology Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
3. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
4. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
5. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
6. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
7. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
8. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
9. Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501
10. Survival Data for Avicenas Amyotrophic Lateral Sclerosis Drug Candidate, AL-02, to be Presented at 18th International Symposium on ALS/MND
11. Leading AIDS Groups Turn Up The Heat on 08 Presidential Candidates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Research and Markets has announced the addition of ... Forecast to 2022" report to their offering. ... The global wound care market was worth $24,482.9 ... of 6.7% during 2016-2022 Among the various wound care products ... the global market in 2015. Among the various applications, surgical wound segment ...
(Date:3/24/2017)... 2017   The Accreditation Council for Medical ... in the pharmaceutical industry has appointed Dr. ... newly formed scientific advisory board. Dr. Chin will ... first ever medical affairs think tank within the ... the ACMA, please visit  www.medicalaffairsspecialist.org .  Connect ...
(Date:3/24/2017)... , March 24, 2017 FinancialBuzz.com News Commentary   ... Medical cannabis products around the ... Inc., projects that the global medical cannabis market will reach a value ... is a major market for the new growing industry. By the end ... legally buy and sell medical cannabis. More conservative states like ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... March 27, 2017 , ... ... training, today announced the launch of a new research study, The Business Readiness ... needed to execute that strategy, and the actual success of achieving individual and ...
(Date:3/27/2017)... , ... March 27, 2017 , ... Janet Schloz is still in shock after receiving ... days I’ve had in a long time,” she said. , She thinks the coming week ... that I never thought I would have to help my students.” , The award will ...
(Date:3/27/2017)... ... March 27, 2017 , ... Mt. ... launch of a months-long rebranding effort. This includes the introduction of new packaging ... discussions and market research, we learned that a simple, proactive approach to wellness ...
(Date:3/27/2017)... ... ... The homeowner improvement and repair market is expected to reach $317 billion ... renovations is also on the rise. Per a 2017 report, 13% of all households ... to use a licensed contractor.(2) The risks associated with improper renovations—especially tiling—can not only ...
(Date:3/25/2017)... ... , ... Norland at Swissray is pleased to announce the release of the ELITE ... DXA has an active scan window, which is more than double that of existing bone ... area could not undergo an accurate total body bone density or body composition study. ...
Breaking Medicine News(10 mins):